ELCC 2022 – Jordi Remon

Jordi Remon outlines what needs to be considered in the context of neoadjuvant and adjuvant immunotherapy in patients with resectable lung cancer, how tyrosine kinase inhibitors can contribute to effective perioperative treatment, treatment approaches in patients with oncogene-driven lung cancer who develop brain metastases as well as in patients with CNS affection whose tumors do not harbor genetic drivers. Current challenges in selecting the best immunotherapeutic approach for the individual patient with mNSCLC and how to deal with them as well as promising potential predictive biomarkers of ICI in patients with NSCLC are highlighted, too.

Here is the full ELCC 2022 report.

More posts

Oncogene-driven lung cancer: EGFR, METex14, ROS1, RET

The neoadjuvant potential of the third-generation EGFR TKI osimertinib was assessed in the multicenter, single-arm, phase II NEOS study that included patients with resectable, stage II-IIIB N2, EGFR-mutant (ex19del/L858R) adenocarcinoma of the lung. Forty patients received osimertinib 80 mg QD for 6 weeks prior to surgery.

Looking more closely at upcoming and established immunotherapy standards

Adjuvant treatment using immune checkpoint inhibition after complete resection of early-stage lung cancer is being investigated considering the modest survival benefit conferred by platinum-based combination chemotherapy in this setting. IMpower010 was the first phase III immunotherapy study to demonstrate a significant disease-free survival (DFS) improvement in the adjuvant setting after platinum-based chemotherapy. Patients included in this trial had undergone complete resection of stage IB-IIIA NSCLC and subsequently received 1–4 cycles of cis­platin-based chemotherapy.

Preface

The European Lung Cancer Congress (ELCC) that took place virtually on 30th March – 2nd April 2022 effectively disseminated the latest advances in lung and thoracic malignancies and gave 131 speakers from all around the world the chance to present promising new research avenues as well as the opportunity for discussions and new perspectives.